Medication info

Ranitac Injection (Ranitidine Hydrochloride)

Prescription medicationSolutionOral · Intramuscular injection · Intravenous injectionExpired
Ingredient · strength
Ranitidine Hydrochloride›28mg / 1mL
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Brown ampoule containing a colorless to light yellow transparent solution
Packaging
2mL x 50 ampoules
Approval status
Expired

MFDS item code 199702396 · Notified 1997.05.26

This product's status changed to Expired on 2025.04.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of acid-related disorders (ulcers, etc.) and upper gastrointestinal bleeding; prevention of Mendelson syndrome
Who uses it
Adults · Children
Adult dosage
Adults Administer 50mg of ranitidine per dose, 3~4 times daily, by intravenous or intramuscular injection. For intravenous injection, dilute 50mg of this medication in 20ml of saline injection or dextrose injection and inject slowly over at least 2 minutes, or mix it with an infusion solution and administer by intravenous infusion over 2 hours at a rate of 25mg/hr. In cases of upper gastrointestinal bleeding, an effect is generally observed within 1 week; switch to oral administration once oral administration becomes possible. For preanesthetic medication (prevention of Mendelson's syndrome), administer 50mg by intramuscular injection or slowly by intravenous injection over 1 minute, 45~60 minutes before induction of anesthesia. Patients with renal impairment For patients with severe renal impairment and creatinine clearance of 50ml/min or less, reduce the dose to 25mg per dose, or extend the dosing interval and administer 50mg per dose every 18~24 hours. Depending on the patient's condition, 50mg may be administered at 12-hour intervals. Since hemodialysis reduces the plasma concentration of the medication, readjust the dosing schedule immediately after hemodialysis. Adjust the dose appropriately according to age and symptoms.
Children's dosage
Clinical studies in children have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (ulcers, etc.) and upper gastrointestinal bleeding; prevention of Mendelson syndrome

  • Gastric and duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson's syndrome
  • post-surgical ulcers
  • upper gastrointestinal bleeding
  • peptic ulcers
  • acute stress ulcers
  • acute gastric mucosal lesions
View approved original text

This medication treats gastric and duodenal ulcers, and is also effective for Zollinger-Ellison syndrome and gastroesophageal reflux disease. Additionally, it is administered pre-anesthesia to prevent Mendelson’s syndrome and is used post-surgery for the treatment of ulcers and upper gastrointestinal bleeding. It also helps with acute stress ulcers and acute gastric mucosal lesions. It is effective for the treatment and prevention of various digestive-related diseases.

Dosage and Administration

Adult dosage

Adults Administer 50mg of ranitidine per dose, 3~4 times daily, by intravenous or intramuscular injection. For intravenous injection, dilute 50mg of this medication in 20ml of saline injection or dextrose injection and inject slowly over at least 2 minutes, or mix it with an infusion solution and administer by intravenous infusion over 2 hours at a rate of 25mg/hr. In cases of upper gastrointestinal bleeding, an effect is generally observed within 1 week; switch to oral administration once oral administration becomes possible. For preanesthetic medication (prevention of Mendelson's syndrome), administer 50mg by intramuscular injection or slowly by intravenous injection over 1 minute, 45~60 minutes before induction of anesthesia. Patients with renal impairment For patients with severe renal impairment and creatinine clearance of 50ml/min or less, reduce the dose to 25mg per dose, or extend the dosing interval and administer 50mg per dose every 18~24 hours. Depending on the patient's condition, 50mg may be administered at 12-hour intervals. Since hemodialysis reduces the plasma concentration of the medication, readjust the dosing schedule immediately after hemodialysis. Adjust the dose appropriately according to age and symptoms.

Children's dosage

Clinical studies in children have not been established.

Precautions

This medication can introduce glass particles when the injection container is cut, so it should be handled very carefully during use, especially in children and the elderly. It should not be used in patients with hypersensitivity to this medication or its components. In patients with poor kidney function, this medicine may remain in the body for an extended duration, so the dosage should be reduced or the dosing interval increased. Caution should also be exercised in patients with impaired liver function. Patients with a history of drug hypersensitivity or elderly patients should be administered carefully. It is not recommended for patients with a history of acute porphyria as it may provoke seizures. This medication can very rarely cause severe allergic reactions or shock; if any abnormal symptoms appear after administration, discontinue use immediately and seek appropriate treatment. If symptoms of hypersensitivity such as hives, rash, or difficulty breathing occur, discontinue the use of this medication immediately. Blood abnormalities such as leukopenia or thrombocytopenia may occur, so if symptoms like fatigue, bleeding, or fever arise, blood tests should be conducted and administration should be discontinued if necessary. Liver dysfunction may occur; therefore, if jaundice or symptoms suggesting liver dysfunction appear, discontinue treatment immediately. Arrhythmias may appear rarely, and patients with heart disease should exercise caution. Gastrointestinal symptoms such as constipation, nausea, vomiting, and abdominal pain may occur; severe symptoms should prompt consulting a physician. Neurological symptoms such as dizziness, drowsiness, and headaches may appear; if abnormal symptoms persist, discontinuation of administration is recommended. Endocrine symptoms such as gynecomastia or sexual dysfunction have been reported rarely, but the cause is not clear. Muscle pain or arthralgia may occur, and in severe cases, rhabdomyolysis may develop; inform healthcare professionals immediately if muscle pain is severe. Skin reactions such as rash or hair loss may occur rarely. Regular blood, liver, and kidney function tests should be conducted during administration, especially when administered intravenously for more than 5 days, daily monitoring of liver enzyme levels is advised. This medication can interact with other drugs, so patients should inform healthcare professionals of any other medications being taken, especially when used with anticoagulants, requiring close monitoring of blood coagulation status. Women who are pregnant or may become pregnant should carefully discuss the need for this medication with their physician, and it should be used cautiously in nursing mothers as it may pass into breast milk. Safety in pediatric patients has not been fully established, so caution is required when administering to children. In cases of overdose, specific toxic symptoms are rare, but symptomatic treatment such as vomiting or gastric lavage may be necessary, and severe cases may require hemodialysis. Intramuscular injections may cause pain or a hard lump at the injection site; caution is needed. Rapid intravenous injection may slow the heart rate; therefore, intravenous infusion should be administered slowly over at least 2 minutes. This medication may mask symptoms of gastric cancer, so patients with gastric ulcers or new or altered dyspeptic symptoms in middle-aged or older patients should confirm malignancy before use. Prolonged use may necessitate eye-related assessments, so an ophthalmologic examination is recommended.

Side effects

  • Anaphylactic shock
  • urticaria
  • angioedema
  • rash
  • fever
  • bronchospasm
  • hypotension
  • chest pain
  • vascular edema
  • granulocytopenia
Show 60 more
  • elevated serum creatinine levels
  • leukopenia
  • thrombocytopenia
  • myelosuppression
  • aplastic anemia
  • aplastic bone marrow
  • refractory anemia
  • agranulocytosis
  • pancytopenia
  • acquired immune hemolytic anemia
  • eosinophilia
  • generalized weakness
  • fatigue
  • subcutaneous mucosal hemorrhage
  • liver dysfunction
  • jaundice
  • hepatitis
  • bradycardia
  • atrioventricular block
  • tachycardia
  • vasculitis
  • cardiac asystole
  • constipation
  • nausea
  • vomiting
  • abdominal bloating
  • abdominal pain
  • loss of appetite
  • diarrhea
  • acute pancreatitis
  • dizziness
  • drowsiness
  • convulsions
  • headache
  • heaviness in the head
  • insomnia
  • excitement
  • anxiety
  • mental confusion
  • depression
  • hallucinations
  • blurred vision
  • involuntary movement disorders
  • altered consciousness
  • liver-type muscle cramps
  • gynecomastia
  • excessive lactation
  • erectile dysfunction
  • decreased libido
  • arthralgia
  • myalgia
  • rhabdomyolysis
  • skin rash
  • erythema multiforme
  • alopecia
  • glossitis
  • skin itching
  • acute interstitial nephritis
  • injection site pain
  • injection site induration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it should be stored in a tightly sealed container that blocks light. Additionally, it is best to store the medication at room temperature, avoiding extreme heat or cold.

Appearance and packaging

Appearance

Brown ampoule containing a colorless to light yellow transparent solution

Package unit

2mL x 50 ampoules

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.